The adoption of medications in substance abuse treatment: Associations with organizational characteristics and technology clusters

Drug and Alcohol Dependence

Volumn 87, Issue 2-3, 2007, Pages 164-174

  Knudsen, Hannah K ^a   Ducharme, Lori J ^a   Roman, Paul M ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

Agonist medications; Disulfiram; Naltrexone; Technology transfer; Treatment services

Indexed keywords

DISULFIRAM; NALTREXONE; SEROTONIN UPTAKE INHIBITOR;

ACCREDITATION; ADOPTION; ARTICLE; BIVARIATE ANALYSIS; DETOXIFICATION; DRUG CONTROL; DRUG DEPENDENCE TREATMENT; FINANCIAL MANAGEMENT; GOVERNMENT; LOGISTIC REGRESSION ANALYSIS; MEDICAL STAFF; NON PROFIT HOSPITAL; ORGANIZATION AND MANAGEMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL;

COMMUNITY MENTAL HEALTH CENTERS; DISULFIRAM; HUMANS; MULTIVARIATE ANALYSIS; NALTREXONE; NARCOTIC ANTAGONISTS; NATIONAL INSTITUTES OF HEALTH (U.S.); REGRESSION ANALYSIS; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; UNITED STATES;

EID: 33846848094     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2006.08.013     Document Type: Article

References (66)

1. Alexander J.A., and Wheeler J.R.C. Managed care and technical efficiency in outpatient substance abuse treatment units. J. Behav. Health Serv. Res. 25 (1998) 377-397
2. Allison P.D. Logistic Regression Using the SAS System: Theory and Application (1999), SAS Institute Inc., Cary, NC
3. Amass L., Kamien J.B., and Mikulich S.K. Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing for opiate-dependent humans. Drug Alcohol Depend. 61 (2001) 173-181
4. Amass L., Kamien J.B., and Mikulich S.K. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug Alcohol Depend. 58 (2000) 143-152
5. Amass L., Ling W., Freese T.E., Reiber C., Annon J.J., Cohen A.J., McCarty D., Reid M.S., Brown L.S., Clark C., Ziedonis D.M., Krejci J., Stine S., Winhusen T., Brigham G., Babcock D., Muir J.A., Buchan B.J., and Horton T. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA clinical trials network field experience. Am. J. Addict. 13 (2004) S42-S46
6. Anton R.F. Pharmacologic approaches to management of alcoholism. J. Clin. Psychiatr. 62 Suppl 20 (2001) 11-17
7. Brahen L.S., Capone T., Bloom S., Adams H.E., Seniuk M.P., and DeJulio P. An alternative to methadone for probationer addicts: narcotic-antagonist treatment. Contemp. Drug Probl. 7 (1978) 117-132
8. Brewer C., Meyers R.J., and Johnsen J. Does disulfiram help to prevent relapse in alcohol abuse?. CNS Drugs 15 (2000) 329-341
9. Bridge T.P., Fudula P.J., Herbert S., and Leiderman D.B. Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence. Drug Alcohol Depend. 70 (2003) S79-S85
10. Capoccia V.A. The evolution of the Robert Wood Johnson foundation's approach to alcohol and drug addiction. In: Isaacs S.L., and Knickman J.R. (Eds). To Improve Health and Health Care IX (2006), Jossey-Bass, San Francisco 139-160
11. Carroll K.M., Nich C., Ball S.A., McCance E., Frankforter T.L., and Rounsaville B.J. One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: sustained effects of treatment. Addiction 95 (2000) 1335-1349
12. Carroll K.M., Nich C., Ball S.A., McCance E., and Rounsaville B.J. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 93 (1998) 713-728
13. Center for Substance Abuse Treatment (CSAT), 1999. CSAT guidelines for the accreditation of opioid treatment programs. http://dpt.samhsa.gov/guidelines.pdf. Accessed on December 9, 2003.
14. Chandrasekaran R., Sivaprakash B., and Chitraleka V. Five years of alcohol de-addiction services in a tertiary care general hospital. Indian J. Psychiatr. 43 (2001) 58-60
15. Damanpour F. Organizational innovation: a meta-analysis of effects of determinants and moderators. Acad. Manage. J. 34 (1991) 555-590
16. Fudula P.J., Bridge T.P., Herbert S., Williford W.O., Chiang C.N., Jones K., Collins J., Raisch D., Casadonte P., Goldsmith R.J., Ling W., Malkerneker U., McNicholas L., Renner J., Stine S., and Tusel D. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N. Engl. J. Med. 349 (2003) 949-958
17. Fuller B.E., Rieckmann T., McCarty D., Smith K.W., and Levine H. Adoption of naltrexone to treat alcohol dependence. J. Subst. Abuse Treat. 28 (2005) 273-280
18. Gowing, L., Ali, R., White, J., 2004. Buprenorphine for the management of opioid withdrawal. The Cochrane Database of Systematic Reviews 2004, Issue 4. Update Software, Oxford.
19. Greenstein R., O'Brien C.P., Woody G., and McLellan A.T. Naltrexone: a short-term treatment alternative for opiate dependence. Am. J. Drug. Alcohol Abuse 8 (1981) 291-296
20. Horgan C.M., and Levine H. The substance abuse treatment system: what does it look like and whom does it serve?. In: Lamb S., Greenlick M.R., and McCarty D. (Eds). Bridging the Gap between Practice and Research: Forging Partnerships with Community-based Drug and Alcohol Treatment (1998), National Academy Press, Washington, DC 186-197
21. Hubbard R.L., Craddock S.G., Flynn P.M., Anderson J., and Etheridge R.M. Overview of 1-year follow-up outcomes in the drug abuse treatment outcome study (DATOS). Psychol. Addict. Behav. 11 (1997) 261-278
22. Hunt R.R. How effective are pharmacologic agents for alcoholism?. J. Fam. Pract. 51 (2002) 577
23. Jaffe J.H., and O'Keeffe C. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend. 70 (2003) S3-S11
24. Johnson A.J., and Roman P.M. Predicting closure of private substance abuse treatment facilities. J. Behav. Health Serv. Res. 29 (2002) 115-125
25. Johnson R.E., Chutuape M.A., Strain E.C., Walsh S.L., Stitzer M.L., and Bigelow G.E. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N. Engl. J. Med. 343 (2000) 1290-1297
26. Johnson R.E., Jaffe J.H., and Fudula P.J. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 267 (1992) 2750-2755
27. Knudsen H.K., and Roman P.M. Modeling the use of innovations in private treatment organizations: the role of absorptive capacity. J. Subst. Abuse Treat. 26 (2004) 353-361
28. Knudsen H.K., Roman P.M., Ducharme L.J., and Johnson J.A. Organizational predictors of pharmacological innovation adoption: the case of disulfiram. J Drug Issues 35 (2005) 559-574
29. Koch A.L., Arfken C.L., and Schuster C.R. Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability. Drug Alcohol Depend. 83 (2006) 274-278
30. Kosten T.R., George T.P., and Kosten T.A. Potential of dopamine agonists in drug addiction. Expert. Opin. Investig. Drugs 11 (2002) 491-499
31. Kranzler H.R. Pharmacotherapy of alcoholism: gaps in knowledge and opportunities for research. Alcohol Alcoholism 35 (2000) 537-547
32. Kranzler H.R., and Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin. Exp. Res. 25 (2001) 1335-1341
33. In: Lamb S., Greenlick M.R., and McCarty D. (Eds). Bridging the Gap between Practice and Research: Forging Partnerships with Community-based Drug and Alcohol Treatment (1998), National Academy Press, Washington, DC
34. Ling, W., Amass, L., Shoptaw, S., Annon, J.J., Hillhouse, M., Babcock, D., Brigham, G., Harrer, J., Reid, M., Muir, J., Buchan, B., Orr, D., Woody, G., Krejci, J., Ziedonis, D., and the Buprenorphine Study Protocol Group, 2005. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction. 100, 1090-1100.
35. Lintzeris N., Bell J., Bammer G., Jolley D.J., and Rushworth L. A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal. Addiction 97 (2002) 1395-1404
36. Litten R.Z., and Allen J.P. Medications for alcohol, illicit drug, and tobacco dependence: an update of research findings. J. Subst. Abuse Treat. 16 (1999) 105-112
37. Mark T.L., Woody G.E., Juday T., and Kleber H.D. The economic costs of heroin addiction in the United States. Drug Alcohol Depend. 61 (2001) 195-206
38. Mark T.L., Kranzler H.R., and Song X. Understanding US addiction physicians' low rate of naltrexone prescription. Drug Alcohol Depend. 71 (2003) 219-228
39. Mark T.L., Kranzler H.R., Song X., Bransberger P., Poole V.H., and Crosse S. Physicians' opinions about medications to treat alcoholism. Addiction 98 (2003) 617-626
40. Mattick, R.P., Breen, C., Kimber, J., Davoli, M. 2003. Methadone maintenance therapy versus no opiate replacement therapy for opiate dependence. The Cochrane Library, Issue 2. Update Software, Oxford.
41. McLellan A.T., and McKay J.R. The treatment of addiction: what can research offer practice?. In: Lamb S., Greenlick M.R., and McCarty D. (Eds). Bridging the Gap between Practice and Research: Forging Partnerships with Community-based Drug and Alcohol Treatment (1998), National Academy Press, Washington, DC 147-185
42. Mee-Lee D.L., Gartner L., Miller M.M., Shulman G.D., and Wilford B.B. Patient Placement Criteria for the Treatment of Substance-related Disorders. 2nd ed. (1996), American Society of Addiction Medicine (ASAM), Chevy Chase, MD
43. Milne S.H., Blum T.C., and Roman P.M. Quality management in a health care setting: a study of substance abuse treatment centers. In: Fedor D., and Ghosh S. (Eds). Advances in the Management of Organizational Quality 5 (2000), Elsevier Science, New York 215-248
44. National Institutes of Health (NIH), 1997. Consensus Statement: Effective Medical Treatment of Opiate Addiction. U.S. Department of Health and Human Services, Washington, DC.
45. O'Brien C.P., Childress A.R., McLellan A.T., Ternes J., and Ehrman R. Use of naltrexone to extinguish opioid conditioned responses. J. Clin. Psychiatr. 45 9 (1984) 53-56
46. O'Malley S.S., Jaffe A., Change G., Schottenfeld R.S., Meyer R.E., and Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch. Gen. Psychiatr. 49 (1992) 881-887
47. Pani P.P., Maremmani I., Pirastu R., Tagliamonte A., and Gessa G.L. Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend. 60 (2000) 39-50
48. Perry J.L., and Rainey H.G. The public-private distinction in organization theory: a critique and research strategy. Acad. Manage. Rev. 13 (1988) 182-201
49. Rodgers J.H., and Barnett P.G. Two separate tracks? a national multivariate analysis of differences between public and private substance abuse treatment programs. Am. J. Drug Alcohol Abuse 26 (2000) 429-442
50. Rogers E.M. Diffusion of Innovations. 4th ed. (1995), Free Press, New York
51. Roman P.M., and Johnson A.J. Adoption and implementation of new technologies in substance abuse treatment. J. Subst. Abuse Treat. 22 (2002) 1-8
52. Rosenheck R., and Kosten T. Buprenorphine for opiate addiction: potential economic impact. Drug. Alcohol Depend. 63 (2001) 253-262
53. Saxon A.J., and McCarty D. Challenges in the adoption of new pharmacotherapies for addiction to alcohol and other drugs. Pharmacol. Ther. 108 (2005) 119-128
54. Schottenfeld R.S., Pakes J.R., Oliveto A., Ziedonis D., and Kosten T.R. Buprenorphine versus methadone maintenance for concurrent opioid dependence and cocaine abuse. Arch. Gen. Psychiatr. 54 (1997) 713-720
55. Simpson D.D. A conceptual framework for transferring research to practice. J. Subst. Abuse. Treat. 22 (2002) 171-182
56. Strain E.C., Stitzer M.L., Liebson I.A., and Bigelow G.E. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am. J. Psychiatr. 151 (1994) 1024-1030
57. Streeton C., and Whelan G. Naltrexone, a relapse prevention maintenance treatment for alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcoholism 36 (2001) 544-552
58. Substance Abuse and Mental Health Services Administration (SAMHSA), 2002. The DASIS Report: Facilities Providing Methadone/LAAM Treatment to Clients with Opiate Addiction. SAMHSA/Office of Applied Studies, Rockville, MD.
59. Thomas C.P., Wallack S.S., Lee S., McCarty D., and Swift R. Research to practice: adoption of naltrexone in alcoholism treatment. J. Subst. Abuse Treat. 24 (2003) 1-11
60. Volpicelli J., Alterman A.I., Hayashida M., and O'Brien C.P. Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatr. 49 (1992) 876-880
61. Walmsley G.L., and Zald M.N. The Political Economy of Public Organizations (1973), Lexington Books, Lexington, MA
62. Walsh S.L., and Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend. 70 (2003) S13-S27
63. Ward J., Hall W., and Mattick R.P. Role of maintenance treatment in opiate dependence. Lancet 353 (1999) 221-226
64. White W.L. Slaying the Dragon: The History of Addiction Treatment and Recovery in America (1998), Chestnut Health Systems, Bloomington, IL
65. Yahr H.T. A national comparison of public- and private-sector alcoholism treatment delivery system characteristics. J. Stud. Alcohol 49 (1986) 233-239
66. Yu, C.Y., Muthen, B., 2002. Evaluation of Model Fit Indices for Latent Variable Models with Categorical and Continuous Outcomes (Technical Report). University of California at Los Angeles, Graduate School of Education & Information Studies, Los Angeles, CA.